Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CFD | P00746 | 1/20 | 0.43 |
| ▸ | TTR | P02766 | 2/20 | 0.42 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6097299 | 0.92 | KDM4E (0.59) | KDM4EPOLBCFDLPAR1 | |
| SCHEMBL6097508 | 0.89 | CFD (0.48) | KDM4ECFDALDH1A1HPGDKMT2A | |
| SCHEMBL6096874 | 0.85 | FOLH1 (0.56) | KDM4EPOLBCFDALDH1A1HPGD | |
| SCHEMBL6097214 | 0.85 | CFD (0.64) | KDM4ECFDALDH1A1HPGDKMT2A | |
| SCHEMBL6094427 | 0.85 | TSHR (0.44) | ALDH1A1HPGDKMT2A | |
| SCHEMBL6095834 | 0.85 | MEN1 (0.57) | KDM4EPOLBALDH1A1HPGDKMT2A | |
| SCHEMBL6098381 | 0.84 | CFD (0.43) | KDM4ECFDALDH1A1HPGDKMT2A | |
| SCHEMBL6097631 | 0.83 | ALDH1A1 (0.44) | KDM4EALDH1A1KMT2A | |
| SCHEMBL6096932 | 0.82 | KLKB1 (0.55) | CFDALDH1A1 | |
| SCHEMBL6093775 | 0.82 | PPARA (0.43) | KDM4EPOLBALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7064124-B2 | NF-κB inhibitor containing substituted benzoic acid derivative as active ingredient | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2006-06-20 | — | — | US | claimed |
| US-7064124-B2 | NF-κB inhibitor containing substituted benzoic acid derivative as active ingredient | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2006-06-20 | — | — | US | disclosed |
| US-20040122244-A1 | Nf-kappa b inhibitor containing substituted benzoic acid derivative as active ingredient | DAIICHI ASUBIO PHARMA CO., LTD. (JP) | 2004-06-24 | — | — | US | disclosed |
| EP-1314712-A1 | NF-KAPPA-B INHIBITOR CONTAINING SUBSTITUTED BENZOIC ACID DERIVATIVE AS ACTIVE INGREDIENT | Daiichi Suntory Pharma Co., Ltd. (JP) | 2003-05-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122244-A1 | Nf-kappa b inhibitor containing substituted benzoic acid derivative as active ingredient | NFKBIA, NFKB1, IKBKB | KDM4E 1491/4885POLB 294/4885CFD 2791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.